US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

61.14

-0.8805-1.42%

Post-market: 61.140.00000.00%16:10 EDT

Volume:21.46K

Turnover:1.32M

Market Cap:287.37M

PE:20.00

High:62.20

Open:62.20

Low:60.99

Close:62.02

52wk High:64.10

52wk Low:39.76

Shares:4.70M

Float Shares:4.70M

Volume Ratio:0.44

T/O Rate:0.46%

Dividend:1.53

Dividend Rate:2.50%

EPS(TTM):3.06

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim

Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Top Midday Gainers

MT Newswires Live

Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright

Roivant Sciences rises 17.6%

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co

Top Premarket Gainers

MT Newswires Live

Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results

Roivant Sciences Jumps After Lung Disease Drug Meets Main Goal in Mid-Stage Study

Shares of Roivant Sciences up 21.1% Premarket After Experimental Lung Disease Drug Meets Main Goal in Mid-Stage Study

THOMSON REUTERS

Guardant Health's Breast Cancer Diagnostic Approved by US FDA

MT Newswires Live

Roivant Says Phase 2 PHocus Trial Shows Mosliciguat Cuts Pulmonary Vascular Resistance 56.3% in PH-ILD

Rothschild & Co Redburn Initiates Guardant Health at Buy

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/PTH/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"PTH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","market":"US","secType":"STK","nameCN":"Invesco Dorsey Wright Healthcare Momentum ETF","latestPrice":61.1419,"timestamp":1789761600000,"preClose":62.0224,"halted":0,"volume":21463,"hourTrading":{"tag":"盘后","latestPrice":61.1419,"preClose":61.1419,"latestTime":"16:10 EDT","volume":22,"amount":1346.21146,"timestamp":1789762204191,"change":0,"changeRate":0,"amplitude":0.001114},"delay":0,"changeRate":-0.014196483850995735,"floatShares":4700000,"shares":4700000,"eps":3.057033,"marketStatus":"Post-Mkt","change":-0.8805,"latestTime":"09-18 18:08:53 EDT","open":62.1967,"high":62.1967,"low":60.985,"amount":1315080,"amplitude":0.019536,"askPrice":69.83,"askSize":100,"bidPrice":54.21,"bidSize":100,"shortable":3,"etf":1,"ttmEps":3.057033,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789776000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":62.0224,"sharesOutstanding":2480000,"nav":60.77493,"aum":287465418.9,"dividendRate":0.024953,"bidAskSpread":0.00195,"preHourTrading":{"tag":"盘前","latestPrice":62.0224,"preClose":62.0224,"latestTime":"04:00 EDT","volume":1,"amount":62.0224,"timestamp":1789718420500,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":61.1419,"preClose":61.1419,"latestTime":"16:10 EDT","volume":22,"amount":1346.21146,"timestamp":1789762204191,"change":0,"changeRate":0,"amplitude":0.001114},"volumeRatio":0.442301,"impliedVol":0.0872,"impliedVolPercentile":0.243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTH\",,,,,undefined,":{"symbol":"PTH","floatShares":4700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.442301,"shares":4700000,"dividePrice":1.5257,"high":62.1967,"amplitude":0.019536,"preClose":62.0224,"low":60.985,"week52Low":39.76,"pbRate":"--","week52High":64.1,"institutionHeld":0,"latestPrice":61.1419,"eps":3.057033,"divideRate":0.024953,"volume":21463,"delay":0,"ttmEps":3.057033,"open":62.1967,"prevYearClose":49.701,"prevWeekClose":60.7692,"prevMonthClose":60.7941,"prevQuarterClose":59.76,"fiveDayClose":60.7692,"twentyDayClose":62.111,"sixtyDayClose":55.6532},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTH\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PTH","amount":1.52645,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2024-06-24","symbol":"PTH","amount":0.02545,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-24","defaultRemindTime":1719235800000,"name":"Invesco Dorsey Wright Healthcare Momentum ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-24","currency":"USD","dateTimestamp":1719201600000,"payDate":"2024-06-28"},{"market":"US","date":"2023-07-17","symbol":"PTH","defaultRemindTime":1689600600000,"type":"split","dateTimestamp":1689566400000,"forFactor":1,"toFactor":3,"ratio":0.3333333333333333}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTH\",market:\"US\",,,undefined,":[{"executeDate":"2024-06-24","recordDate":"2024-06-24","paymentDate":"2024-06-28","value":0.02545,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-26","value":1.52645,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PTH\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1156894230","title":"LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894230?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:08","pubTimestamp":1788998900,"startTime":"0","endTime":"0","summary":"LIFETECH SCI (01302) has announced that it received an official written notice from the National Medical Products Administration (NMPA) on September 9, 2026, confirming that the LantvalTM aortic...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","LNGR","RSPH","01302","GDOC","159883","BK1583","LGHT","09996","BK1600","IEIH","PTH","AGNG","MDEV","MEDX","BK1574","HART"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK4588","LFSC","EKG","PTH","BK4551","HELX","LU0320765992.SGD","GNOM","GNMX","GH","GDOC","LU0889565916.HKD","LU0109394709.USD","BK4585","BK4196","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666041535","title":"Roivant Sciences Price Target Raised to $46.00/Share from $42.00 by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2666041535","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666041535?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:30","pubTimestamp":1788960600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666769587","title":"Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666769587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666769587?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:10","pubTimestamp":1788952232,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Collegium Pharmaceutical (COLL), Revolution Medicine...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-collegium-pharmaceutical-coll-revolution-medicines-rvmd-and-intellia-therapeutics-ntla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","NTLA","LABU","BK4139","CANC","IE00BFTCPJ56.SGD","BK4585","LU0109394709.USD","BK4007","IE00B2B36J28.USD","LU0029874061.USD","BK4588","RVMD","HCSG","IDNA","COLL","LU0889565916.HKD","IE00BJT1NW94.SGD","LU1861558580.USD","BK4137","IE0009355771.USD","PTH","BK4581","LU1861559042.SGD","LU0320765992.SGD","XBI","LU0128526141.USD","BK4535","IE0009354923.USD","XLV","IE0002141913.USD","BK4556","IE00B4R5TH58.HKD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","IBBJ","TBXU","MRNY","BBH","JHMH","APXH","PBPH","AZNH","SURI","RSPH","PINK","PTH","SYNB","MEDI","IBRN","WDNA","GDOC","FXH","IEIH","GNOM","PSCH","PJP","GSKH","IBB","FTXH","CURE","SBIO","XPH","BBP","IBBQ","FHLC","NVIB","BIB","CNCR","HRTS","CANC","GNMX","FBT","BME","LFSC","MDTX","MNTL","GPCR","MEDX","LLYX","PBE","PSIL","HYLG","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666637458","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666637458","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666637458?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:27","pubTimestamp":1788888467,"startTime":"0","endTime":"0","summary":"Roivant Sciences  shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints.More than 13.5 million shares of the company traded intraday compared with a daily average of about 6.26 million.Intel  is expected to raise personal computer central processing unit prices by another 10% in early October, Digitimes reported, citing supply chain sources.Shares jumped 10%, with intraday trading volume at over 86.0 million, versus the stock's daily average of about 113.4 million.Pharvaris  said that a global phase 3 study of deucrictibant extended-release tablets met the primary endpoint of reducing the mean monthly attack rate by 83%, compared with placebo, in people with hereditary angioedema.Wedbush Securities adjusted Pharvaris' price target to $50 from $42 while maintaining its outperform rating.Shares climbed 10% as int","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2764262908.HKD","INTC","IE000M9KFDE8.USD","LU0154236417.USD","HK0000304797.USD","LU0742534661.SGD","LU0251131958.USD","LU2360106780.USD","BK4139","HK0000304805.HKD","IE0000B7K699.USD","IE000WAW04H5.SGD","BK4512","LU0251142724.SGD","BK4554","BK4529","LU0082616367.USD","SOXX","BK4007","BK4543","AIQ","CHPS","LU2250418816.HKD","INT","AIS","LU0274383776.USD","PHVS","LU2244417387.USD","LU0048573561.USD","LU2089985449.USD","LU1852331112.SGD","LU0187121727.USD","LU2357627491.SGD","LU0081259029.USD","BK4575","BK4535","XNTK","IE000SO60NU8.SGD","DRIV","BK4602","QQQA","LU2543165471.USD","BK4515","LINT","BK4585","BK4612","BK4605","BK4534","LU2764263203.CNY","SINTCmain","IE000MB6IJN5.SGD","LU0149725797.USD","BK4588","LU0719512351.SGD","04335","TTEQ","LU0321505439.SGD","LU2148611432.USD","LU0321505868.SGD","LU2931357623.SGD","BK4579","ROIV","FTXL","BK4141","LU0097036916.USD","LU0056508442.USD","BK4550","INYY","PTH","IE000BZT7R73.USD","BK4527","LU0859254822.USD","LEGR","LU2720916845.USD","LU2764263039.SGD","IE000F7OJYX1.SGD","INTW","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666492371","title":"Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2666492371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666492371?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:35","pubTimestamp":1788885318,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Roivant Sciences (ROIV) to $47 from $41 and keeps a Buy rating on the shares. The firm believes m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-47-from-41-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-47-from-41-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376643","title":"Roivant Sciences rises 17.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376643?lang=en_us&edition=fundamental","pubTime":"2026-09-08 22:05","pubTimestamp":1788876358,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) is up 17.6%, or $6.15 to $41.08. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-rises-17-6-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-rises-17-6-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PTH","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665752763","title":"U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665752763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665752763?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:57","pubTimestamp":1788875845,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, NovartisSeptember 8 (Reuters)-Wall Street's main indexes were mixed at open on Tuesday as fresh hostilities in the Middle East pushed oil price","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL6N4500HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245673.USD","LU0868494617.USD","SRPT","ROIV","BIB","ICLN","IBBQ","USNG","LU0187121727.USD","LU2324357040.USD","SGXZ57979304.SGD","LU1989772923.USD","LU1720051017.SGD","BBH","BK4168","PUL","VCLN","IBB","LU0353189763.USD","IE00B19Z4B17.USD","IE00B4R5TH58.HKD","BK4121","IE0034235188.USD","BK4602","LU1548497426.USD","LU0154245756.USD","LU0878866978.SGD","BK4581","BK4599","HYDR","LU0823414478.USD","BK4124","LU0109394709.USD","LU0889565916.HKD","LU2506951792.HKD","LU1989771016.USD","BK4007","LU1791710582.SGD","BK4170","LU1153585028.USD","LU2506952097.USD","SEI","LU0823417737.USD","LU0208291251.USD","PHVS","BK4179","DYN","GNOM","BK4535","LU0823416689.USD","LU0011850046.USD","SG9999001440.SGD","LU0068578508.USD","CQTM","LU0289739699.SGD","LU0114720955.EUR","ALV","LU1061106388.HKD","LU1571399168.USD","SG9999001176.SGD","LU0476273544.USD","AMGN","BK4505","SIMS","LU2506951875.HKD","IONC","BK4541","ILMN","BK4533","LU2087625088.SGD","BEC","LU1878469433.USD","BK4578","LU1983299246.USD","LU2491049909.HKD","LU0029874061.USD","IE0002141913.USD","LU2362540622.SGD","QTUP","LU1989764664.SGD","LU1861558580.USD","LU0128526141.USD","BK4102","BEG","LU0238689110.USD","LU2357305700.SGD","BE","LU0138981039.USD","LU0267386448.USD","BK4141","LU0266013472.USD","BK4120","IONZ","BHVN","LU2491050154.USD","SMOG","IONL","LU0345769128.USD","LU0211331839.USD","LU2506952170.USD","UPGR","IE0031619046.USD","LU1057294990.SGD","BEZ","LU1642822529.SGD","IONS","BK4182","NVS","MEDX","VTWG","IBAT","LU2098885051.SGD","LU0225283273.USD","RGTI","LU0444973449.USD","LU0882574055.USD","IE0009354923.USD","LU2357125470.USD","BK4566","RGTX","LU0444971666.USD","LU1489326972.SGD","LU0077335932.USD","LU0353189680.USD","LU1064131342.USD","LU0985489474.SGD","BK4567","LU0433182093.SGD","LU1989764748.USD","TBXU","LU1989772840.SGD","LU2362541513.USD","ZAP","LU2264538146.SGD","IE00B66KJ199.SGD","LU0070302665.USD","CTEC","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4532","IONX","LU1366192091.USD","LU0345769631.USD","LU0823414551.USD","P","LU1815336760.USD","LU1791710400.SGD","SHAK","LU0122379950.USD","LU2244417387.USD","LU2491050071.SGD","LU1718418525.SGD","04332","BK4588","PBE","FRNW","LU1291159041.SGD","LU2242649171.HKD","RGTZ","SG9999001176.USD","SG9999013999.USD","IONQ","LU1093756168.USD","BK4591","LU1023059063.AUD","BK4131","LU0957808578.USD","LU2242646821.SGD","BK4548","RGTU","LU2089984988.USD","LU2543165471.USD","LU0058720904.USD","LU2112291526.USD","SGML","LU0823417653.USD","UNFI","ABM","BSX","RGYY","NTLA","LU0432979614.USD","PTH","XES","LU1720051108.HKD","GNMX","BK4139","BK4082","BK4585","IE00BJT1NW94.SGD","LU2242652126.USD","IE00B7SZL793.SGD","IE00BJJMRZ35.SGD","LU1861559042.SGD","PJP","WQTM","EGGY","IOYY","IE0009355771.USD","LU1988902786.USD","LU0048584097.USD","BK4504","OIH","CNRG","CHRW","RGTC","BK4534","BK4597","WATS","LU2294711713.HKD","LU2362541273.HKD","LU1093756325.SGD","LU1804176565.USD","LU0528227936.USD","LU1303367103.USD","LU0950375773.USD","LU2265009873.SGD","LU2506951958.HKD","LU0320765489.SGD","LU2468319806.SGD","SRPU","PPH","BK4209","IE00B2B36J28.USD","BK4556","LU0251132253.USD","BEX","LU2249611893.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665891373","title":"Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665891373","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665891373?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:55","pubTimestamp":1788872154,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were mostly lower pre-bell Tuesday, coming off a three-day weekend as t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2360108059.USD","LU1291159041.SGD","TEK","LU0084288322.USD","FFGX","LU2506952097.USD","FOWF","BK4532","BK4599","LU0077335932.USD","LU2506952170.USD","LU1037948897.HKD","IE00BQXX3F31.USD","GSID","LU1023059063.AUD","LU0124676726.USD","LU1244550221.USD","BK4512","LU1934455277.USD","LU1267930490.SGD","BK4605","LU0861579265.USD","LU1282649067.USD","LU0359202008.SGD","LU1548497426.USD","LU2125154778.USD","IFLR","ILOW","LU2112291526.USD","BLOX","AVXC","BK4591","SHLD","CHPX","LU0310799852.SGD","ASMG","LU1366192091.USD","LU0175139822.USD","BK4527","LU2125154935.USD","LU2663582299.SGD","IE0004091025.USD","LU0320765646.SGD","IDEF","LU1623119135.USD","LU0541502299.USD","TSMG","TINS","LU1804176565.USD","PPH","LU2298321311.HKD","LU0823414551.USD","CNEQ","IE0004086264.USD","LU2357305700.SGD","LU1323610961.USD","SMH","ADVE","NVOX","BK4543","TTEQ","LU1852331112.SGD","LU0882574055.USD","LU2092937221.SGD","LU2506951958.HKD","BK4139","AVSE","LU0211328371.USD","NVOC","LU2506951875.HKD","LU1983299246.USD","LU2357125470.USD","LU0143863198.USD","LU0432979614.USD","LU0359201612.USD","LU2237443549.SGD","LU2133065610.SGD","LU2491050071.SGD","LU0316494557.USD","SGXZ99366536.SGD","IE00BQXX3D17.EUR","NVOH","LU1791710582.SGD","BK4187","LU1267930813.SGD","IEFA","LU0266013472.USD","LU0965509283.SGD","LU0792757196.USD","LU2506951792.HKD","MEMX","LMTS","LU0094547139.USD","SPWO","WDGF","LU2237443978.SGD","LU2491050154.USD","BSX","THNR","LU0122379950.USD","LU2750360997.AUD","STSM","LU2294711713.HKD","NVS","SGXZ51526630.SGD","SG9999001176.SGD","LU0889566641.SGD","LU0689626769.HKD","LU2860962120.EUR","ESIM","BK4534","TSMX","LU2491049909.HKD","LU1244550577.SGD","TWSC","BK4526","LU0138981039.USD","LU2750360641.GBP","IE00BJJMRZ35.SGD","LU0345774631.USD","LU0225283273.USD","ASMH","LU1989764664.SGD","LU1989771016.USD","LU0488056044.USD","OZEM","LU2271345857.HKD","LU0345770993.USD","LU0251132253.USD","LU0208291251.USD","LU2360106780.USD","LU1934455194.USD","IE0009355771.USD","LMTL","LU1508157978.USD","LU1057294990.SGD","LU0097036916.USD","LU0082616367.USD","LU0572940350.SGD","LU2237443622.USD","LU0353189763.USD","LU1718418525.SGD","LU0359201885.HKD","LU0823414478.USD","LU1934455863.HKD","LU0889565833.HKD","LU2211814178.USD","EPAI","SG9999004220.SGD","LU0719512351.SGD","LU2471134879.HKD","BK4516","IE00BKPKM429.USD","LU0642271901.SGD","ROIV","DBEF","FENI","LU0823421416.USD","LU1061106388.HKD","TSM","SPTE","LU2471134952.CNY","LU0211327993.USD","IE00BQXX3C00.GBP","LU0048584097.USD","PPA","BK4612","BK4141","WUGI","ASMZ","CWI","LU0882747503.HKD","SG9999001176.USD","LU2458330169.SGD","LU0211331839.USD","LU1917777945.USD","LU1162221912.USD","MISL","PQNT","BK4503","IE00B5TLWC47.USD","LU0238689110.USD","LU2543165471.USD","HBMX","LU0878005551.USD","LU0965509010.AUD","BK4007","IE00B2B36J28.USD","LU0345769128.USD","LU2106854487.HKD","LU1868838027.USD","BK4581","IE00BYQQ9H92.USD","03165","IE00BZ199S13.USD","LMT","CORO","CGDG","IE00BFXG0V08.USD","LU0345769631.USD","LU0070302665.USD","LU1720051108.HKD","IE00BKVL7J92.USD","LU0823417653.USD","SGXZ57979304.SGD","BK4533","LU1803068979.SGD","LU2324357040.USD","CGIC","IE00BFTCPJ56.SGD","LU2041044095.USD","LU2471134523.USD","BK4505","LU1023057109.AUD","MEDX","EFA","LU0264606111.USD","SG9999000418.SGD","LU0384037296.USD","LU0572939691.SGD","LU0109392836.USD","LU1868837565.USD","CGGO","LU0158827781.USD","LU0823421333.USD","BK4602","LU0098860793.USD","LU1712237335.SGD","LU1989772840.SGD","IE00BZ1G4Q59.USD","FDTX","LU2211815571.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0965508806.USD","LU0345774391.USD","ASML","IE00B3M56506.USD","IE00BJT1NW94.SGD","LU2242649171.HKD","TSMY","LU2089283258.USD","LU0187121727.USD","AVEM","LU0267386448.USD","LU2244417387.USD","ASIA","LU1153585028.USD","EMC","UMMA","LU1211504680.USD","LU0823417737.USD","LU1244550494.USD","TSMZ","LU1037948541.HKD","LU0823434740.USD","LU0198837287.USD","IE0004445239.USD","LU0289960550.SGD","LU0345770308.USD","IE00BHPRN162.USD","LU1316542783.SGD","LU2249611893.SGD","LU2087625088.SGD","LU2471134796.USD","LU2247934214.USD","PTH","LU0011850046.USD","AIQ","LU2250418816.HKD","LU1720051017.SGD","LU0823434583.USD","LU2063271972.USD","LU0323591593.USD","LU0072462343.USD","BK4564","EMM","LU1989764748.USD","LU2265009873.SGD","LU2237443382.USD","BK4504","LU2023250504.SGD","LU2111349929.HKD","BK4550","CGNG","LU2054465674.USD","BK4604","LU1791710400.SGD","DBEU","LU0154236417.USD","LU2362540622.SGD","LU0823416689.USD","DIPR","BK4147","LU0056508442.USD","LU0320765489.SGD","LU1093756168.USD","LU1868837722.USD","LU0528227936.USD","BAI","LU0950375773.USD","KNOW","LU0353189680.USD","BK4585","03145","BK4554","BK4588","LU0878004406.USD","ASMU","BK4548","LU2089284900.SGD","LU0965509101.SGD","BK4578","LU1093756325.SGD","TSMU","NVO","LU1282649810.SGD","LU1734074674.USD","LU0114720955.EUR","LU1929549753.HKD","LU1974910355.USD","LU2028103732.USD","LU0541501648.USD","LU2023251221.USD","LU0158827948.USD","LU0348723411.USD","LU1048588211.SGD","LU1989772923.USD","LU0143863784.USD","IE00BD6J9T35.USD","LU2362541513.USD","NATO","SGXZ81514606.USD","BK4082","LU2362541273.HKD","LU2458330243.SGD","SG9999013999.USD","LU2360032135.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373511","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373511?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871865,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN), Guardant Health (GH) and Neurocrine (N...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-guardant-health-gh-and-neurocrine-nbix-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","LU0289739699.SGD","XBI","IBBQ","IE00BJT1NW94.SGD","LU2468319806.SGD","LFSC","PBE","PTH","BK4588","BK4535","LU0154245673.USD","TBXU","FFOX","HELX","AMGN","IE00B2B36J28.USD","LU0029874061.USD","LU0109394709.USD","GDOC","LU2065170008.USD","LU1571399168.USD","LU1061106388.HKD","IE0002141913.USD","GNOM","BK4137","LU1057294990.SGD","BK4585","IE00BFTCPJ56.SGD","IBB","GH","LU0823416689.USD","BK4533","BIB","BK4599","IE0009355771.USD","NBIX","LU2242646821.SGD","LABU","BBH","HCSG","LU0154245756.USD","LU0889565916.HKD","BK4534","LU2242652126.USD","GNMX","PJP","EKG","BK4139","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","GPCR","PBPH","HYLG","XPH","HRTS","TBXU","APXH","JHMH","MRNY","JDOC","GNMX","BBH","BBP","MDTX","SURI","LFSC","IBBQ","FBT","IBRN","PSIL","AZNH","GDOC","MEDI","SYNB","BIB","CURE","FTXH","MEDX","LENZ","PBE","PTH","IBBJ","MNTL","FXH","FHLC","LLYX","GNOM","RSPH","BME","NVIB","PINK","PSCH","PJP","GSKH","WDNA","IDNA","CANC","SBIO","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378332","title":"Guardant Health Price Target Announced at $203.00/Share by Rothschild & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378332?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:26","pubTimestamp":1788870360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","EKG","GDOC","PTH","BK4588","GNMX","LU0889565916.HKD","BK4585","FFOX","LFSC","LU0320765992.SGD","GNOM","BK4551","HELX","LU0109394709.USD","BK4196","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322709","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322709","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322709?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:15","pubTimestamp":1788866115,"startTime":"0","endTime":"0","summary":"CEA Industries  shares were up over 63% in Tuesday's premarket activity following a 6.1% rise in the prior trading session on Thursday.GMEX Robotics  stock was 23% higher, swinging from the 5.5% loss in the earlier sessionRoivant Sciences  shares were up 23% after the company said its Pulmovant unit's phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD, met its primary and secondary endpoints.Upstream Bio  stock was 11% higher after the company said it presented phase 2 clinical trial results for its lead severe asthma treatment candidate, verekitug, at the European Respiratory Society Congress in Barcelona.Eightco  shares were up 8% following a 6.8% fall in the prior session.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4220","UPB","ROIV","BK4007","BK4139","BNC","BK4086","PTH","GMEX","BK4136","BK4200","ORBS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324029","title":"Roivant Sciences Shares Rise on Positive Mid-Stage Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324029","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324029?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:51","pubTimestamp":1788864660,"startTime":"0","endTime":"0","summary":"Shares of Roivant Sciences climbed after the company disclosed what it called positive results from a mid-stage trial evaluating its treatment for some instances of pulmonary hypertension, or high blo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PTH","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665248463","title":"Roivant Sciences Jumps After Lung Disease Drug Meets Main Goal in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665248463","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665248463?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:25","pubTimestamp":1788863137,"startTime":"0","endTime":"0","summary":"BUZZ-Roivant Sciences jumps after lung disease drug meets main goal in mid-stage study** Shares of Roivant SciencesROIV.Orise 21.7% to $42.50 premarket** The drug developer's Pulmovant unit says its experimental inhaled therapy, mosliciguat, met the primary goal in a mid-stage study in patients with pulmonary hypertension associated with interstitial lung disease** It is a condition where high blood pressure develops in the lung arteries due to scarring or inflammation in the lungs** The study showed a 56.3% placebo-adjusted reduction in resistance in the lungs' blood vessels at 16 weeks** The drug also met secondary goals: improving six-minute walk distance by 35.2 meters vs placebo; reducing levels of NT-proBNP, a biomarker of cardiac strain, by 53.2% at week 16** Cough, a common side effect associated with inhaled prostacyclin therapies, was reported in 12.1% of patients receiving mosliciguat vs 18.2% on placebo** ROIV says it has already initiated the late-stage study of moslicigua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N4500PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321166","title":"Shares of Roivant Sciences up 21.1% Premarket After Experimental Lung Disease Drug Meets Main Goal in Mid-Stage Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321166","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321166?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:10","pubTimestamp":1788862233,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN44Z0J3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","PTH","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321994","title":"Guardant Health's Breast Cancer Diagnostic Approved by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321994","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321994?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:08","pubTimestamp":1788862114,"startTime":"0","endTime":"0","summary":"Guardant Health's  Guardant360 CDx has been approved by the US Food and Drug Administration as a companion diagnostic for advanced metastatic breast cancer, the company said Friday.The specific indication for the diagnostic combination is to identify patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer harboring tumors with specific mutations before radiographic progression who may benefit from treatment with AstraZeneca's  Etcamah, the company said.The approval is based on data from a clinical trial showing a 56% reduction in the risk of progression or death, the company said.Shares of the company were up 1% in recent premarket trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GH","LU2237443978.SGD","LU2237443549.SGD","LU2417539215.USD","BK4196","BK4585","GNOM","LU1267930573.SGD","BK4551","EKG","LU0058720904.USD","LU0289739699.SGD","LU2237443895.HKD","LABU","LU2462157665.USD","LU0320765992.SGD","GDOC","FFOX","IE00B3T34201.USD","LU0128525929.USD","PTH","LU0029864427.USD","LU0889565916.HKD","LU0432979614.USD","LFSC","GNMX","LU2468319806.SGD","LU2237443622.USD","LU0310800379.SGD","LU2089984988.USD","LU2237443465.HKD","LU0109394709.USD","LU2237443382.USD","BK4588","LU1829250122.USD","BK4535","BK4568","LU0708994859.HKD","AZN","LU2456880835.USD","LU2236285917.USD","HELX","AZNH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732139","title":"Roivant Says Phase 2 PHocus Trial Shows Mosliciguat Cuts Pulmonary Vascular Resistance 56.3% in PH-ILD","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732139","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732139?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:02","pubTimestamp":1788861725,"startTime":"0","endTime":"0","summary":"Roivant says Phase 2 PHocus trial shows mosliciguat cuts pulmonary vascular resistance 56.3% in PH-ILDRoivant reported positive Phase 2 results for inhaled mosliciguat in pulmonary hypertension tied t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDLbzhjky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665213403","title":"Rothschild & Co Redburn Initiates Guardant Health at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665213403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665213403?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:01","pubTimestamp":1788861705,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","LU0109394709.USD","BK4588","GNOM","PTH","FFOX","LU0889565916.HKD","BK4551","LFSC","BK4535","GH","HELX","EKG","GDOC","BK4585","GNMX","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}